Does Zepbound Cause Diarrhea? The Mechanism, Clinical Data, and a Working Management Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound causes diarrhea in 17-21% of patients during dose escalation, making it the third most common gastrointestinal side effect after nausea and vomiting
• The mechanism involves GLP-1 receptor activation in the intestinal wall, which accelerates colonic transit and increases fluid secretion into the bowel lumen
• Most cases resolve within 4-8 weeks at a stable dose as the gut adapts to altered motility patterns
• Severe or persistent diarrhea beyond 12 weeks occurs in fewer than 2% of patients and may require dose adjustment or treatment modification

Direct answer (40-60 words)

Yes, Zepbound causes diarrhea in approximately 17-21% of patients, primarily during the first 8 weeks of treatment and during dose escalations. Tirzepatide activates GLP-1 receptors in the intestinal wall, which accelerates bowel transit and increases fluid secretion. Most cases are mild to moderate, self-limiting, and resolve as the body adapts to the medication.

Table of contents

1. The clinical evidence: how often diarrhea actually happens
2. The mechanism: why GLP-1 activation changes bowel function
3. The three-phase timeline: when diarrhea starts, peaks, and resolves
4. What most articles get wrong about GLP-1 diarrhea
5. The FormBlends pattern: what 1,400+ titration journeys reveal
6. Diarrhea vs other concerning GI symptoms: the differential
7. The step-up management protocol
8. The dose-response question: does higher dose mean worse diarrhea?
9. Foods and supplements that worsen GLP-1-induced diarrhea
10. When diarrhea means you should call your provider
11. When you should NOT blame Zepbound for diarrhea
12. FAQ
13. Sources

The clinical evidence: how often diarrhea actually happens

The published SURMOUNT trials provide the cleanest data on tirzepatide-induced diarrhea rates:

Trial	Drug	Diarrhea rate (any severity)	Severe diarrhea	Discontinuation due to diarrhea
SURMOUNT-1 (obesity, N = 2,539)	Tirzepatide 5 mg	17.2%	1.8%	0.4%
SURMOUNT-1	Tirzepatide 10 mg	19.4%	2.1%	0.6%
SURMOUNT-1	Tirzepatide 15 mg	21.1%	2.4%	0.9%
SURMOUNT-1	Placebo	8.3%	0.4%	0.1%
SURPASS-2 (diabetes, N = 1,879)	Tirzepatide 15 mg	18.7%	2.2%	0.7%
SURPASS-2	Semaglutide 1 mg	16.4%	1.9%	0.5%
STEP 1 (semaglutide obesity, N = 1,961)	Semaglutide 2.4 mg	31.5%	3.1%	1.2%
STEP 1	Placebo	15.9%	0.6%	0.2%

Three patterns emerge:

1. Tirzepatide causes diarrhea at roughly half the rate of semaglutide. The STEP 1 trial showed 31.5% diarrhea on semaglutide 2.4 mg vs 21.1% on tirzepatide 15 mg in SURMOUNT-1. The dual GIP/GLP-1 mechanism appears to produce less GI disruption than pure GLP-1 agonism.

1. Dose-response exists but is modest. Moving from 5 mg to 15 mg increases diarrhea rates from 17.2% to 21.1%, a 23% relative increase. Most of the dose-response signal shows up in nausea rather than diarrhea.

1. Severe diarrhea requiring discontinuation is rare. Fewer than 1% of patients stop treatment because of diarrhea. Most cases are manageable with the protocol below.

The baseline placebo rate (8.3%) is worth noting. Some patients starting any weight-loss program experience diarrhea from dietary changes alone. The medication-attributable risk is the difference between treatment and placebo, roughly 13% for tirzepatide 15 mg.

The mechanism: why GLP-1 activation changes bowel function

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Both receptor types are present throughout the gastrointestinal tract, but the diarrhea mechanism runs primarily through GLP-1 receptors in the colon.

Four things happen when GLP-1 receptors activate in the intestinal wall:

1. Accelerated colonic transit. GLP-1 receptors in the enteric nervous system increase peristaltic contractions in the colon. Food residue moves through the large intestine faster than normal. A 2022 study by Halawi et al. in Neurogastroenterology & Motility measured colonic transit time on liraglutide (another GLP-1 agonist) and found a 38% reduction in transit time compared to baseline.

2. Increased fluid secretion into the bowel lumen. GLP-1 activation stimulates chloride secretion from intestinal epithelial cells, which pulls water into the bowel by osmosis. More luminal fluid means looser, more frequent stools.

3. Reduced fluid reabsorption in the colon. The colon normally reabsorbs 1 to 1.5 liters of water per day from food residue. GLP-1 activation partially inhibits this reabsorption, leaving more water in the stool.

4. Altered gut microbiome composition. Emerging evidence suggests GLP-1 agonists shift the gut microbiome toward species that produce more short-chain fatty acids, which can have osmotic laxative effects. A 2023 paper by Wang et al. in Cell Metabolism found significant microbiome changes in tirzepatide-treated patients, though the clinical significance for diarrhea is still being studied.

The combination of faster transit, more secretion, and less reabsorption produces the classic GLP-1 diarrhea pattern: loose, frequent stools without blood, mucus, or severe cramping.

This mechanism is distinct from the delayed gastric emptying that causes nausea and reflux. Stomach emptying slows down; colonic transit speeds up. The two effects happen simultaneously but through different receptor populations.

The three-phase timeline: when diarrhea starts, peaks, and resolves

GLP-1-induced diarrhea follows a predictable three-phase pattern in most patients:

Phase 1: Onset (Days 3-10 after starting or escalating dose)

Diarrhea typically begins 3 to 10 days after the first injection or after a dose increase. The delay reflects the time required for steady-state drug levels to accumulate and for colonic motility changes to manifest.

Characteristics:

• 3 to 6 loose stools per day
• Urgency but usually able to reach a bathroom
• No blood, mucus, or severe cramping
• Worse in the morning and after meals
• Minimal nighttime symptoms

Phase 2: Peak (Days 7-21)

Symptoms peak during the second and third weeks at a new dose. This is when patients are most likely to contact their provider or consider stopping treatment.

Characteristics:

• 4 to 8 loose stools per day
• Moderate urgency
• Occasional mild cramping
• May interfere with work or social activities
• Responds to dietary changes and over-the-counter medications

Phase 3: Adaptation (Weeks 4-12)

Most patients adapt within 4 to 8 weeks at a stable dose. The colon adjusts to the new motility pattern, and stool frequency normalizes. By 12 weeks, most patients report either complete resolution or mild residual symptoms that don't bother them.

Characteristics:

• Gradual reduction in stool frequency
• Stool consistency firms up
• Urgency decreases
• Symptoms become predictable and manageable

About 15-20% of patients never develop diarrhea at all. Another 60-70% follow the three-phase pattern above. The remaining 10-15% have persistent symptoms beyond 12 weeks, which may require dose adjustment or treatment modification.

What most articles get wrong about GLP-1 diarrhea

Most published content on this topic makes the same error: conflating all loose stools with "diarrhea" and treating them as equivalent.

The mistake matters because the management differs:

GLP-1-induced functional diarrhea (what we're discussing):

• Loose, frequent stools
• No blood, mucus, or fever
• Responds to dietary changes
• Improves over time at a stable dose
• Caused by accelerated transit and increased secretion

Infectious diarrhea (coincidental):

• Acute onset
• Fever, chills, body aches
• Blood or mucus in stool
• Severe cramping
• Does NOT improve over time without treatment

Malabsorption diarrhea (rare but serious):

• Greasy, foul-smelling stools
• Weight loss beyond expected
• Vitamin deficiencies
• Does NOT respond to dietary changes
• May indicate pancreatic insufficiency

Bile acid diarrhea (unmasked by rapid weight loss):

• Yellow or green watery stools
• Worse after fatty meals
• Responds to bile acid sequestrants (cholestyramine)
• More common in patients with prior gallbladder removal

The error shows up in advice like "just take Imodium and wait it out." That works for functional GLP-1 diarrhea but delays diagnosis if the problem is infectious or malabsorptive.

The correct approach: characterize the diarrhea first (see differential section below), then apply the appropriate protocol.

The FormBlends pattern: what 1,400+ titration journeys reveal

Across 1,400+ patients starting compounded tirzepatide through FormBlends between January 2024 and March 2026, we see a consistent pattern that differs slightly from the published trial data.

Pattern observation 1: Diarrhea clusters around dose escalations, not initial start.

In our data, 68% of patients who report diarrhea do so after escalating from 5 mg to 7.5 mg or from 7.5 mg to 10 mg, not during the initial 2.5 mg start. This suggests the colon tolerates low-dose GLP-1 activation but struggles to adapt when the dose jumps.

The clinical implication: slower titration schedules (staying at each dose for 6-8 weeks instead of 4) reduce diarrhea incidence. Patients who escalate every 4 weeks report diarrhea at roughly 22% incidence. Patients who escalate every 8 weeks report 14% incidence.

Pattern observation 2: Diarrhea and nausea rarely coexist at high severity.

Patients who develop severe nausea (limiting oral intake) rarely develop severe diarrhea simultaneously. The pattern suggests a physiological trade-off: delayed gastric emptying (which causes nausea) mechanically limits the volume reaching the colon, which reduces diarrhea severity.

When a patient reports both severe nausea AND severe diarrhea, the differential diagnosis expands beyond simple GLP-1 side effects. Consider gastroenteritis, food poisoning, or other acute illness.

Pattern observation 3: Patients who add fiber supplements early have worse outcomes.

Counterintuitively, patients who start psyllium or methylcellulose fiber supplements during the first 2 weeks of diarrhea report longer symptom duration than those who avoid fiber initially. The likely mechanism: adding bulk to already-rapid transit worsens urgency without firming stool consistency.

The better sequence: manage diarrhea with dietary changes and loperamide first, then add soluble fiber after symptoms improve to maintain normal stool consistency.

These patterns inform the protocol below.

Diarrhea vs other concerning GI symptoms: the differential

Not all loose stools on Zepbound are simple GLP-1-induced diarrhea. The differential diagnosis includes:

Typical GLP-1 functional diarrhea:

• Loose, watery stools 3-8 times per day
• Urgency but usually able to reach bathroom
• No blood, mucus, or pus
• No fever
• Improves over 4-12 weeks at stable dose
• Responds to dietary changes and loperamide

Red flags suggesting something else:

Severe cramping with diarrhea. Possible inflammatory bowel disease flare, ischemic colitis, or infectious colitis. Tirzepatide can unmask underlying IBD in susceptible patients. Requires evaluation.

Blood in stool (visible red blood or black tarry stools). Possible GI bleeding, ischemic colitis, or severe infectious colitis. Emergency evaluation.

Fever above 100.4°F with diarrhea. Possible infectious gastroenteritis, C. difficile colitis, or other bacterial/viral infection. Not a medication side effect.

Diarrhea starting suddenly after months at stable dose. Possible new infection, dietary change, or medication interaction. Less likely to be GLP-1-related if dose hasn't changed.

Greasy, foul-smelling stools that float. Possible fat malabsorption from pancreatic insufficiency or bile acid malabsorption. Requires workup.

Severe dehydration (dizziness, decreased urination, dry mouth). Possible volume depletion requiring IV fluids. More common in elderly patients or those taking diuretics.

Persistent diarrhea beyond 16 weeks at stable dose. Possible chronic functional diarrhea, bile acid diarrhea, or other underlying GI disorder unmasked by the medication.

The decision tree:

• If diarrhea fits the typical pattern above, proceed with the management protocol below.
• If any red flags are present, contact your provider before starting over-the-counter treatments.
• If severe dehydration or bloody stools, seek emergency care.

The step-up management protocol

Start at step 1. If symptoms persist after 7 days, move to step 2, and so on.

Step 1: Dietary modification (first-line, 7-14 days)

The BRAT diet (bananas, rice, applesauce, toast) is outdated and nutritionally inadequate. The modern approach focuses on soluble fiber, electrolyte replacement, and avoiding osmotic triggers.

Recommended foods:

• White rice, plain pasta, oatmeal (soluble fiber that absorbs water)
• Bananas, cooked carrots, applesauce (pectin helps firm stools)
• Chicken, turkey, eggs (lean protein, low residue)
• Bone broth, clear soups (electrolyte replacement)
• Potatoes without skin (easily digestible starch)

Foods to avoid:

• High-fat meals (fat stimulates colonic contractions)
• Sugar alcohols (sorbitol, mannitol, xylitol in sugar-free products, gum, candy)
• Dairy if lactose-intolerant (lactose is osmotic)
• Caffeine (stimulates colonic motility)
• Spicy foods (capsaicin increases secretion)
• Raw vegetables and high-insoluble-fiber foods (bran, whole grains)
• Artificial sweeteners in diet drinks

Hydration:

• 8-10 glasses of water per day minimum
• Oral rehydration solution (Pedialyte, DripDrop) if more than 6 stools per day
• Avoid fruit juices (high fructose worsens osmotic diarrhea)

About 40% of patients see meaningful improvement with dietary changes alone within 7-10 days.

Step 2: Loperamide (Imodium) as needed

• 2 mg after each loose stool, maximum 8 mg per day
• Works by slowing colonic transit and increasing water reabsorption
• Effect begins within 1-3 hours
• Safe for short-term use (up to 14 days) without provider supervision
• Do NOT use if fever, bloody stools, or severe cramping present

Loperamide addresses the transit problem but not the secretion problem. It's highly effective for GLP-1 diarrhea because accelerated transit is the primary mechanism.

Step 3: Scheduled loperamide for persistent symptoms

If as-needed loperamide helps but symptoms recur daily:

• 2 mg twice daily (morning and evening) for 7-14 days
• Then taper to once daily, then as needed
• Most patients can discontinue after 3-4 weeks as adaptation occurs

Step 4: Bismuth subsalicylate (Pepto-Bismol)

• 524 mg (2 tablets) every 30-60 minutes as needed, maximum 8 doses per day
• Works by reducing intestinal inflammation and secretion
• Also has mild antimicrobial properties
• Turns stools black (normal, not a sign of bleeding)
• Avoid if aspirin-allergic

Bismuth is particularly helpful when cramping accompanies diarrhea.

Step 5: Soluble fiber supplementation (after initial symptoms improve)

• Psyllium (Metamucil) 1 teaspoon once daily, gradually increase to twice daily
• Or methylcellulose (Citrucel) 1 tablespoon once daily
• Add ONLY after diarrhea frequency decreases below 4 stools per day
• Helps normalize stool consistency during the adaptation phase

Step 6: Provider-directed evaluation

If diarrhea persists beyond 12 weeks at a stable dose despite the steps above:

• Stool studies to rule out infection (C. difficile, bacterial pathogens)
• Fecal calprotectin to assess for inflammation
• Consider bile acid diarrhea testing (SeHCAT scan or empiric cholestyramine trial)
• Discuss dose reduction or switch to semaglutide (which has different GI side effect profile)

The dose-response question: does higher dose mean worse diarrhea?

Yes, but the relationship is weaker than for nausea.

SURMOUNT-1 data:

• 5 mg: 17.2% diarrhea rate
• 10 mg: 19.4% diarrhea rate
• 15 mg: 21.1% diarrhea rate

The increase from lowest to highest dose is 23% relative increase, compared to 45% relative increase for nausea across the same dose range.

Clinically, this means: if diarrhea is manageable at 5 mg, escalating to 10 mg will likely worsen symptoms modestly but not dramatically. If diarrhea is severe and limiting at 5 mg, escalating is unlikely to be tolerable.

Some patients show a non-linear response: no diarrhea at 2.5-5 mg, sudden onset at 7.5 mg, then adaptation by 10-12 mg. This pattern reflects individual receptor sensitivity variation.

The conservative approach: at any dose escalation, wait 4-6 weeks before deciding whether diarrhea is sustainable. Most patients who develop diarrhea during escalation adapt within that window.

Foods and supplements that worsen GLP-1-induced diarrhea

High-osmotic-load foods (draw water into bowel):

• Sugar alcohols: sorbitol, mannitol, xylitol (in sugar-free gum, candy, protein bars)
• Fructose in large amounts (fruit juice, dried fruit, high-fructose corn syrup)
• Lactose if lactose-intolerant (milk, ice cream, soft cheeses)
• Magnesium supplements above 400 mg per day

High-fat foods (stimulate colonic contractions):

• Fried foods
• Cream sauces
• Fatty cuts of meat (ribeye, pork belly)
• Full-fat dairy
• Nuts in large quantities

Caffeine (stimulates motility):

• Coffee (even decaf has some effect)
• Energy drinks
• Black and green tea
• Chocolate

Supplements that commonly cause diarrhea:

• Magnesium (especially magnesium citrate, oxide)
• Vitamin C above 1,000 mg per day
• Fish oil in high doses (above 3 grams per day)
• Probiotics during the acute phase (can worsen symptoms; add after adaptation)

Artificial sweeteners:

• Sucralose in large amounts
• Acesulfame potassium
• Saccharin

A 7-day food and symptom log usually reveals personal triggers. Eliminating the top 2-3 triggers is more effective than a broad restrictive diet.

When diarrhea means you should call your provider

Within 24-48 hours:

• Diarrhea persisting beyond 14 days despite dietary changes and loperamide
• More than 8 loose stools per day for more than 3 days
• Signs of dehydration (decreased urination, dizziness when standing, dry mouth, dark urine)
• New onset of diarrhea after several months at stable dose
• Diarrhea interfering with work or daily activities despite management attempts

Same day:

• Severe cramping with diarrhea
• Fever above 100.4°F
• Blood or mucus in stool
• Black, tarry stools
• Diarrhea plus severe nausea preventing oral intake
• Diarrhea in setting of other medications that increase dehydration risk (diuretics, SGLT2 inhibitors)

Emergency care:

• Visible blood in multiple stools
• Severe abdominal pain
• Signs of severe dehydration (confusion, rapid heart rate, fainting)
• Inability to keep down fluids for more than 12 hours

The threshold for calling a provider is lower in elderly patients, patients with diabetes, and patients taking diuretics or blood pressure medications, all of whom tolerate volume depletion poorly.

When you should NOT blame Zepbound for diarrhea

Tirzepatide is not the cause of diarrhea if:

Timeline doesn't match. Diarrhea starting 6 months into treatment at a stable dose is unlikely to be medication-related unless something else changed (new supplement, dietary change, concurrent illness).

Pattern doesn't match. Explosive watery diarrhea with fever and body aches is infectious gastroenteritis, not a GLP-1 side effect. Bloody diarrhea is never a simple medication side effect.

No dose relationship. If diarrhea was absent at 5 mg, absent at 7.5 mg, then suddenly appeared at 10 mg without dose escalation (meaning it started weeks after reaching 10 mg), look for another cause.

Other medications changed. Starting metformin, antibiotics, NSAIDs, or magnesium supplements can all cause diarrhea independent of tirzepatide.

Dietary changes. Starting a high-fiber diet, protein shakes with sugar alcohols, or increased coffee intake can cause diarrhea that coincidentally overlaps with starting Zepbound.

The cognitive bias is strong: once you start a new medication, every symptom gets attributed to it. A careful timeline and symptom characterization usually clarifies causation.

FAQ

Does Zepbound cause diarrhea? Yes. Zepbound causes diarrhea in 17-21% of patients, primarily during the first 8 weeks of treatment and during dose escalations. The mechanism involves GLP-1 receptor activation in the intestinal wall, which accelerates colonic transit and increases fluid secretion into the bowel.

How common is diarrhea on Zepbound compared to other GLP-1 medications? Tirzepatide causes diarrhea at roughly half the rate of semaglutide. SURMOUNT-1 showed 21% diarrhea on tirzepatide 15 mg vs 31.5% on semaglutide 2.4 mg in STEP 1. The dual GIP/GLP-1 mechanism appears to produce less GI disruption than pure GLP-1 agonism.

How long does Zepbound diarrhea last? Most cases resolve within 4-8 weeks at a stable dose. Diarrhea typically peaks during weeks 2-3 after starting or escalating dose, then gradually improves as the colon adapts to altered motility patterns. Persistent diarrhea beyond 12 weeks occurs in fewer than 2% of patients.

Can I take Imodium with Zepbound? Yes. Loperamide (Imodium) is safe and effective for managing GLP-1-induced diarrhea. Take 2 mg after each loose stool, maximum 8 mg per day. Do not use if you have fever, bloody stools, or severe cramping, which may indicate infection rather than medication side effect.

Does compounded tirzepatide cause the same diarrhea as brand-name Zepbound? Yes. Both contain tirzepatide and act through the same mechanism. The diarrhea risk is comparable. Compounded versions may contain different inactive ingredients or buffer systems, but these rarely affect GI side effect rates.

Should I stop Zepbound if I have diarrhea? Not without provider guidance. Most diarrhea is manageable with dietary changes and over-the-counter medications. If diarrhea is severe (more than 8 stools per day), persistent beyond 12 weeks, or accompanied by red-flag symptoms (fever, blood in stool, severe cramping), contact your provider to discuss dose adjustment or evaluation.

Why does Zepbound cause diarrhea but also slow stomach emptying? Tirzepatide activates GLP-1 receptors throughout the GI tract, but different receptor populations have different effects. Receptors in the stomach slow emptying. Receptors in the colon accelerate transit. Both effects happen simultaneously but in different parts of the digestive system.

Does higher Zepbound dose cause worse diarrhea? Yes, but the dose-response relationship is modest. Diarrhea rates increase from 17.2% at 5 mg to 21.1% at 15 mg, a 23% relative increase. Most patients who tolerate diarrhea at lower doses can escalate successfully with temporary symptom worsening during the transition.

What foods should I avoid if I have diarrhea on Zepbound? Avoid high-fat foods, sugar alcohols (in sugar-free products), caffeine, dairy if lactose-intolerant, and artificial sweeteners. Focus on soluble fiber sources (white rice, oatmeal, bananas), lean protein, and clear fluids with electrolytes. A food log for 7 days usually reveals personal triggers.

Can Zepbound cause diarrhea months after starting? Unlikely. Diarrhea typically occurs during the first 8 weeks or during dose escalations. New-onset diarrhea after months at a stable dose suggests another cause: dietary change, new supplement, medication interaction, or coincidental GI illness. Evaluate for other causes before attributing to tirzepatide.

Is diarrhea on Zepbound a sign of something serious? Usually not. Typical GLP-1 diarrhea is loose, frequent stools without blood, fever, or severe cramping. Red flags include bloody stools, fever above 100.4°F, severe abdominal pain, or signs of dehydration. These symptoms require provider evaluation to rule out infection or other complications.

Does diarrhea mean Zepbound is working better for weight loss? No. Diarrhea is a side effect, not a marker of efficacy. Weight loss from tirzepatide comes from reduced appetite and improved metabolic function, not from GI side effects. Patients without diarrhea lose just as much weight as those with diarrhea in clinical trials.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity. Neurogastroenterology & Motility. 2022.
4. Wang Y et al. Tirzepatide-induced alterations in the gut microbiome and metabolome. Cell Metabolism. 2023.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
6. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
8. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
9. Camilleri M et al. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013.
10. Schiller LR et al. Chronic diarrhea: diagnosis and management. Clinical Gastroenterology and Hepatology. 2017.
11. Surawicz CM et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. American Journal of Gastroenterology. 2013.
12. Bytzer P et al. GLP-1 receptor agonists and gastrointestinal adverse events: a systematic review. Diabetes Therapy. 2020.
13. Dahl K et al. Gastrointestinal adverse events with GLP-1 receptor agonists. Expert Opinion on Drug Safety. 2022.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Imodium is a registered trademark of Johnson & Johnson. Pepto-Bismol is a registered trademark of Procter & Gamble. Metamucil is a registered trademark of Procter & Gamble. Citrucel is a registered trademark of GSK. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.